REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX) has announced a conference call scheduled for March 5, 2026, at 8:00 a.m. ET, during which the company will discuss its financial results for the fourth quarter and full year ending December 31, 2025. This call presents an opportunity for investors and analysts to gain insights into REGENXBIO's operational highlights and future outlook.

Listeners can register for the live webcast via the link provided in the announcement, and a replay will be accessible about two hours after the call concludes on the company's investor relations website. Participants are encouraged to join the call 15 minutes early to ensure a timely connection.

Founded in 2009, REGENXBIO is at the forefront of gene therapy, harnessing the potential of adeno-associated virus (AAV) technology to develop transformative treatments for rare and retinal diseases. The company's late-stage pipeline includes notable investigational therapies such as RGX-202 for Duchenne muscular dystrophy, clemidsogene lanparvovec (RGX-121) for mucopolysaccharidosis type II (MPS II), RGX-111 for mucopolysaccharidosis type I (MPS I), and suragene lomparvovec (ABBV-RGX-314) for wet age-related macular degeneration and diabetic retinopathy, in partnership with AbbVie.

REGENXBIO's innovative approach has resulted in the treatment of thousands of patients using its AAV gene therapy platform, laying a foundation for potentially life-changing therapies that could enhance healthcare delivery for millions. For more information about REGENXBIO and its ongoing initiatives, interested parties can visit the company’s website at www.regenxbio.com.

REGENXBIO Inc. (Nasdaq: RGNX) is poised for an important conference call scheduled on March 5, 2026, where it will discuss its financial results for the fourth quarter and the entire year of 2025. Investors should approach this event with a keen eye on the company's operational highlights and the performance of its gene therapy pipeline, particularly given their significant advancements in curative therapies for rare and retinal diseases.

With continued innovation in AAV gene therapy, REGENXBIO has made substantial strides, particularly with programs such as RGX-202 for Duchenne muscular dystrophy, and RGX-121 and RGX-111 for different forms of MPS diseases, developed in collaboration with Nippon Shinyaku. Additionally, their partnership with AbbVie on surabgene lomparvovec (ABBV-RGX-314) illustrates their strong positioning in treating conditions like wet AMD and diabetic retinopathy. These developments not only highlight the potential for transformative treatments but also suggest a robust commercial outlook, which investors should factor into their assessments.

What's critical for stakeholders attending the call will be any updates regarding clinical trial progress, regulatory filings, and strategic collaborations. It would be wise for investors to monitor management's commentary on revenue expectations and cost management strategies, as the biotechnology sector often grapples with high operational costs amidst rigorous R&D efforts.

In preparation for this call, reaching out to the investor relations team could yield additional insights into the upcoming financial report. Investors should consider both short-term volatility associated with earnings reports and long-term potential driven by the company's innovative pipeline. Managing positions with discretion in light of market response post-call will be essential for optimizing investment outcomes in REGENXBIO’s evolving landscape.